The Global Innovative Product 莱特灵®/Ryaltris® (Olopatadine Hydrochloride and Mometasone Furoate Monohydrate Nasal Spray) Is Approved for Commercialization in China
R&D Centers
R&D People
Projects in Progress
The Global Innovative Product 莱特灵®/Ryaltris® (Olopatadine Hydrochloride and Mometasone Furoate Monohydrate Nasal Spray) Is Approved for Commercialization in China
The Global Innovative Product TP-03 for the Treatment of Demodex Blepharitis Is Approved for Commercialization in China
The NDA of Grand Pharma’s Global Innovative RDC TLX591-CDx Is Accepted by the NMPA
PHARMACEUTICAL TECHNOLOGY
NUCLEAR MEDICINE ANTI-TUMOR DIAGNOSIS AND TREATMENT AS WELL AS CEREBRO- CARDIOVASCULAR PRECISION INTERVENTIONAL DIAGNOSIS AND TREATMENT TECHNOLOGY
BIOTECHNOLOGY